Microbiotica to Present at Top Microbiome Conferences

Cambridge, UK, 22 May 2018 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June.

Microbiome Invest - 23 May, London, UK

Dr Mike Romanos, co-founder and CEO of Microbiotica, will join panellists David Cook, Seres Therapeutics and Luc Sterkman, Caelius Therapeutics B.V for a panel entitled The Journey of a Microbiome Biotech.

The Microbiome Movement – Drug Development Summit, 20-22 June, Boston, USA

· 3pm, 21 June - Dr Romanos will participate in the panel discussion The Supporting Role of the Pre-clinical CRO When Conducting Microbiome Research, joined by panellists from the Janssen Human Microbiome Institute, Charles River Laboratories and Finch Group Therapeutics. Read Mike’s speaker interview here.

· 10.00am, 22 June Dr Trevor Lawley, co-founder and CSO will present Culturing the Unculturable to Enable Precision Metagenomics.

The Microbiotica team will also attend the 3^rd Annual Advances in Immuno-oncology Congress, 24-25 May, London, UK and the 7^th IHMC International Human Microbiome Congress, 26-28 June, Killarney, Ireland.

-ENDS-

Notes to Editors

About Microbiotica www.microbiotica.com

The Company was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute. Microbiotica’s founders are Dr Mike Romanos, Dr Trevor Lawley and Prof Gordon Dougan, FRS.

CIC and IP Group are co-investors in Microbiotica, with a £4m contribution from each party to provide total initial funding of £8m.

Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute.

About the Microbiome

Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.

For further information please contact: